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Abstract
Identification of somatic mutations in cancer is a major goal for understanding and monitoring the events related to cancer
initiation and progression. High resolution melting (HRM) curve analysis represents a fast, post-PCR high-throughput
method for scanning somatic sequence alterations in target genes. The aim of this study was to assess the sensitivity and
specificity of HRM analysis for tumor mutation screening in a range of tumor samples, which included 216 frozen pediatric
small rounded blue-cell tumors as well as 180 paraffin-embedded tumors from breast, endometrial and ovarian cancers (60
of each). HRM analysis was performed in exons of the following candidate genes known to harbor established commonly
observed mutations: PIK3CA, ERBB2, KRAS, TP53, EGFR, BRAF, GATA3, and FGFR3. Bi-directional sequencing analysis was used
to determine the accuracy of the HRM analysis. For the 39 mutations observed in frozen samples, the sensitivity and
specificity of HRM analysis were 97% and 87%, respectively. There were 67 mutation/variants in the paraffin-embedded
samples, and the sensitivity and specificity for the HRM analysis were 88% and 80%, respectively. Paraffin-embedded
samples require higher quantity of purified DNA for high performance. In summary, HRM analysis is a promising moderate-
throughput screening test for mutations among known candidate genomic regions. Although the overall accuracy appears
to be better in frozen specimens, somatic alterations were detected in DNA extracted from paraffin-embedded samples.
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Introduction
Recently, the first cancer genomes to be completely sequenced
have revealed an unanticiapted breadth and complexity of somatic
alterations [1,2,3]. The discovery of somatic sequence alterations,
has accelerated the investigation of ir underlying mechanisms in
carcinogenesis. Somatic alterations implicated in cancer develop-
ment and growth advantage are called driver mutations. However,
the majority of somatic alterations in cancer genomes are a
consequence of genomci instability and appear to be passenger
or bystander mutations that are unlikely to be involved in
oncogenesis [4,5]. Large-scale sequencing studies have shown that
the prevalence and signature of somatic mutations in human
cancers are highly variable [5,6,7,8]. Based on these studies, we
can estimate that the majority of somatic mutations in cancer cells
are likely to be passenger mutations, whereas a minority are
estimated to be driver mutations [5,7]. The full landscape of the
prevalence of mutations as well as their functional consequences
will not be appreciated until thousands of cancer genomes have
been sequenced.
Sequencing cancer genomes is a formidable task that requires
expensive technologies and computational support to assemble
large portions of the genome. Because of the intense interest in
identifying key somatic alterations, investigation has focused on
techniques for screening or analyzing regions of interest. Most
studies have concentrated on coding regions and adjacent intronic
or putative regulatory regions [9]. One of those techniques is the
high resolution melting (HRM) curve analysis, a polymerase chain
reaction (PCR) based high-throughput assay for detecting DNA
sequence variation by measuring changes in the melting of a DNA
duplex, that has been used successfully with DNA extracted from
both frozen and paraffin-embedded tissue [10,11,12].
HRM specific PCR products are generated to interrogate
conformational differences, also known as dissociation curve
analysis, using conventional real-time PCR platforms. It is utilized
in combination with a double stranded DNA binding dye in
order to characterize primer-related non-specific amplification
(or primer dimer) for detection of a specific target. Single-base
changes in PCR products are detected by altered HRM properties
monitored through the release of fluorescent double strand DNA
binding dye [13,14]. The development of accurate and inexpen-
sive instruments that offer HRM capabilities, and new fluorescent
dyes, make this method attractive for targeted mutation scanning
and also germ line genotyping. HRM analysis is utilized to
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reducing significantly the amount of DNA sequencing to be
performed [15,16,17,18,19,20].
The aim of this study was to assess the sensitivity and specificity
of an inexpensive HRM analysis platform for mutation scanning of
single-base variation in a range of tumor samples: frozen pediatric
small rounded blue-cell tumors and paraffin-embedded tumors
from breast, endometrium and ovarian cancers. Bi-directional
sequence analysis was performed to determine the accuracy of this
DNA HRM technology.
Methods
Ethics Statement
The Institutional Review Board for the Polish Breast, Ovarian,
and Endometrial Cancer Study were approved by the National
Cancer Institute (NCI), at Bethesda, MD, the M. Sklodowska
Institute of Oncology and Cancer Center in Warsaw, and the
Institute of Occupational Medicine (IOM) in Lodz, both in Poland
[21]. Written informed consent for participation on the studies was
obtained at the participating institutions from all participants
involved.
All frozen samples from pediatric small rounded blue-cell
tumors and obtained from Cooperative Human Tissue Network
(http://chtn.nci.nih.gov/), were anonymized, and our protocol
was reviewed by the Office of Human Subjects Research at
National Institutes of Health, Bethesda, MD, and deemed exempt.
DNA samples
Frozen tissue samples. Snap frozen tumor samples were
obtained from Cooperative Human Tissue Network (http://chtn.
nci.nih.gov/). Neuroblastoma cell lines and their culture con-
ditions are described elsewhere [22]. Genomic DNA was extracted
from frozen primary tumor samples (neuroblastoma, n=140;
rhabdomyosarcoma, n=63) and neuroblastoma cell lines (n=13)
using a published protocol [23]. DNA concentration was quanti-
fied using NanoDrop (Thermo Fisher Scientific, Wilmington, DE),
and then adjusted to the same concentration, 10 ng/mL, for the
12 assays. Matched control genomic DNA was available from
peripheral blood for 43 cancers.
Paraffin-embedded tissue samples. The Polish Breast,
Ovarian, and Endometrial Cancer Study is part of a collaborative
study between the U.S. National Cancer Institute (NCI), the M.
Sklodowska Institute of Oncology and Cancer Center in Warsaw,
and the Institute of Occupational Medicine (IOM) in Lodz [21]
designed to study risk factors for breast, endometrial and ovarian
cancer [24,25,26]. Paraffin blocks of tumor tissue from partici-
pants of this study that underwent surgery were collected. In total,
we included tissue from 60 participants with breast cancer, 60 with
endometrial cancer and 60 with ovarian cancer.
Single 0.6 mm tissue cores targeted to areas with tumor that
had been identified and marked by a pathologist (MES) were
obtained from each tumor block for DNA extraction, using a tissue
microarray coring needle for each sample. Microdissection was
performed for a small proportion of the samples, making it difficult
to accurately assess the percentage of tumor material. Nucleic acid
extraction was performed with the AgencourtH FormaPure
TM kit
(Agencourt Bioscience Corporation, Beverly, MA) according to
the manufacturer’s instructions. To avoid interferences with the
PCR we removed RNA from purified total nucleic acid during
the extraction method. After extraction and purification, DNA
concentration and purity were quantified using NanoDrop
(Thermo Fisher Scientific, Wilmington, DE). Total genomic
DNA extracted with this method yielded an averaged of 2.07 mg
(range 0.03 to 7.69 mg). The purity of DNA for each extraction
method was assessed by measuring the intensity of absorbance of
the DNA solution at wavelengths 260 nm (A260) and 280 nm
(A280).
Selection of exons for screening
The set of exons selected for this mutation scanning analysis
were drawn from cancer genes frequently mutated (PIK3CA,
ERBB2, KRAS, TP53, EGFR, BRAF, GATA3, and FGFR3)i n
published reports, with a particular emphasis on breast, ovarian
and endometrium cancers [5,9,27,28,29,30,31,32]. Also, HRM
analysis for these particular genomic regions had already been
optimized.
Primers and pre-HRM PCR
Primers of the exons, as well as the size of the amplicons, used
for the pre-HRM PCR are listed in Table 1. On average, 40 bp of
the proximal - or 59- intronic region flanking the target exon and
41 bp of the 39 intronic region flanking the target exon were
covered by the amplicon. The only exception was exon 6 of
GATA3, which measures 1462 bp, of which 284 bp correspond to
coding nucleotides. In this particular case, the amplicon did not
extend over the 39 side of the intron (Table 1 for details).
Attention to detail in pre-HRM PCR conditions is paramount
for optimization: 1) design of PCR primers to keep GC content
under or as close as 60% as possible, product size around 200 bp
and avoid known variants within the primer region; 2) selection of
optimal annealing temperatures with gradient PCR; 3) and design
of PCR experiments in a consistent manner: same assay, with
same sample batch and same machine run.
PCR-based analyses for the different genes were performed in
96-well format with 10 mL volumes and included 10 ng of
genomic DNA for frozen samples, and 1 mL of solution containing
genomic DNA for paraffin-embedded tissue samples, with mean
concentration of 25.8 ng/mL (SD=21.7), and ranging from 2
to over 55 ng/mL (first quartile 8.4 ng/mL, and third quartile
36.3 ng/mL). Master Mix that included all deoxynucleoside
triphosphates, Taq polymerase, and the LCGreenH PLUS (Idaho
Technology, Salt Lake City, UT) was used for the pre-HRM PCR.
PCR was performed using a MJ Research PTC 225 Thermal
Cycler (MJ Research, GMI Inc., Ramsey, MN) with an initial
denaturation at 95uC for 2 minutes, followed by 45 cycles of 2 step
temperature cycling of 95uC for 30 seconds, and 66 to 70uC for 30
seconds (PIK3CA, ERBB2, KRAS at 66uC; TP53, EGFR, BRAF at
68uC; GATA3, FGFR3 at 70uC). After PCR, the samples were
heated to 93uC for 30 seconds and then cooled to 25uC before
HRM.
Sample handling
Frozen. HRM analyses were performed in duplicate on all the
samples yielding either frank (n=59) or minimal variations
(n=99) in the normalized HRM curve, and also in 20% randomly
chosen negative samples (n=45). A second round of HRM was
performed to assess the reproducibility of the method, using
known negative controls and positive controls. Frank variations
were defined as those HRM curves interpreted by the software to
be suspicious of harboring a nucleotide change or a mutation/
variant, and were represented in red in the graphics (Figure S1).
Minimal variation on a sample was considered when the software
detected minor variance in the HRM curve with respect to the
averaged wild-type curve without calling it a mutation (3% of all
calls) (Figure S1). These samples were represented either in grey or
green, depending on their degree of separation with the averaged
wild-type curve. All samples with frank or minimal variation of the
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sequenced.
Paraffin-embedded. We analyzed 60 breast cancer samples,
60 endometrial cancer samples and 60 ovarian cancer samples.
The quality of the extracted DNA was measured by the presence
of pre-HRM PCR product in the HRM analysis and by the
presence of a single band on a 1.5% agarose gel [33]. In this set, all
samples were bi-directionally sequenced.
HRM Curve Analysis
Samples were amplified in 96-well plates, and HRM curves
acquisition was performed on a prototype version of the HRM
instrument, LightScanner
TM, using LCGreenH Plus+ Dye (Idaho
Technology, Salt Lake City, UT). Depending on the assay
combination on the plate, HRM range was set to accommodate
each assay individual profile with at least 4uC prior to the first melt
transition on the plate, with a slope of 0.3uC/s, and at least 3
degrees after the last fragment has completely melted.
Since HRM was performed in this study as the screening
technology, the curves were analyzed using custom LightScan-
ner
TM software (Idaho Technology, Salt Lake City, UT). Normali-
zation and background subtraction were first performed by fitting
an exponential to the background surrounding the HRM trans-
itions of interest. The normalized HRM curves were temperature-
overlaid, to eliminate slight temperature errors between wells
or runs. Difference plots of these normalized and temperature-
overlaid curves were obtained by taking the fluorescence
difference of each curve from the average wild-type curve at all
temperature points [13,14]. HRM curves with a plot interpreted
by the software to be different from the averaged wild-type curve
were considered to be suspicious of harboring a nucleotide
change or a mutation/variant (Figure S1). These analytical
methods have been applied previously to mutation scanning
[34,35].
Bi-directional Sequence Analysis
Bi-directional sequence analysis was performed with primers
that were designed by extending each oligonucleotide used in the
pre-HRM PCR with a universal sequencing primer: M13 forward
(TGTAAAACGACGGCCAGT) or M13 reverse (CAGGAAA-
CAGCTATGACC). PCR conditions for sequencing analysis were
performed in 96-well format with 10 mL volumes and included
1 mL of amplified DNA from the pre-HRM PCR reaction.
Genomic DNA was used only when the sequence reaction failed
with amplified DNA. PCR products were sequenced using a
modified ABI PrismH BigDye Terminator protocol (Applied
Biosystems, Foster City, CA). Unincorporated dyes terminators
and salts were removed utilizing a Sephadex G-50 (Sigma, St
Louis, MO) spin columns in a MultiScreenH-HV 96-well filter
plate (Millipore, Billerica, MA). The reactions were run on an ABI
Table 1. Primers for pre-HRM DNA amplification.
Gene Exon Size (bp)
Direction
primer Primer
Intron 59
coverage (bp)
Intron 39
coverage (bp)
PIK3CA 10 258 Forward ATCCAGAGGGGAAAAATATGAC 58 -
Reverse TGAGATCAGCCAAATTCAGTTAT - 74
FGFR3 13 195 Forward TGCCTCCCACCCCTTCC 21 -
Reverse AGGCGTCCTACTGGCAT - 51
ERBB2 25 200 Forward ACATGGGTGCTTCCCATTC 22 -
Reverse GCTCCTTGGTCCTTCACCTA - 22
TP53 5
1 186 Forward GCCCTGACTTTCAACTCTG 39 -
Reverse CCTCACAACCTCCGTCAT - -
TP53 5
2 115 Forward TGGCCATCTACAAGCAGTC - -
Reverse CAGCCCTGTCGTCTCTC - 34
TP53 7 200 Forward GGCGCACTGGCCTCATCT 39 -
Reverse AGAGGCTGGGGCACAGCA - 51
EGFR 23 213 Forward CAGCAGGGTCTTCTCTGTTTC 23 -
Reverse GAAAATGCTGGCTGACCTAAAG - 34
KRAS 2 208 Forward GTGACATGTTCTAATATAGTCACATTTTC 46 -
Reverse GGTCCTGCACCAGTAATATG - 40
BRAF 15 184 Forward AGATCTACTGTTTTCCTTTACTTACTACACC 35 -
Reverse AATCAGTGGAAAAATAGCCTCAATTCT - 30
GATA3 5 190 Forward GATTTCACCCTCTCCTCTCTCCC 32 -
Reverse AGCCCTGTTCTTGCTGATCC - 32
GATA3 6
1 194 Forward GTGGAACCCTTCTTGGTGTG 88 -
Reverse AGTCCTCCAGTGAGTCATGC - -
GATA3 6
2 154 Forward AAATGTCTAGCAAATCCAAAAAGTGCAA - -
Reverse GTGGTCAGCATGTGGCTGGA - -79
1Proximal region.
2Distal region.
doi:10.1371/journal.pone.0014522.t001
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were analyzed and compared using two software packages
(SeqScape
TM v2.5 and Variant Reporter
TM v1.0, both from
Applied Biosystems, Foster City, CA) and reviewed by two
independent reviewers [9]. When the software was unable to align
and assemble the forward and the reverse sequences the sample
was considered to have failed the sequencing process for the
purpose of this study. For the paraffin-embedded assays that did
not performed as well as their frozen counterparts (specifically
exons from genes TP53 and GATA3), PCR conditions as well as
their primers were modified to improve sequencing. This included
generating primers that extended across more of the genomic
regions or slide 20–30 bp up or down stream. But we noted that
the new, specific assays failed to optimize while testing different
regions would alter the purpose of the study. In summary,
sequencing error rate was 2.5% for frozen specimens and 20.0%
for paraffin-embedded.
Nucleotide changes detected by sequencing were classified as
novel alterations or known SNPs (or Single Nucleotide Polymor-
phisms) if found in dbSNP, Build 130, from the NCBI (www.ncbi.
nlm.nih.gov/projects/SNP/), using Genewindow (genewindow.
nci.nih.gov) [36].
Statistical Analysis
The association between the quantity of DNA extracted from
the paraffin-embedded tissue (levels: #10 ng/mL, 11–20 ng/mL,
21–30 ng/mL, and .30 ng/mL) and a successful pre-HRM PCR
assay, measured either by the presence of a single amplicon in
agarose gel or the presence of a DNA product at the HRM
analysis, was performed by logistic regression analysis. Agreement
between 2 variables (or reliability) was determined by a Kappa
test. Kappa values less than 0.40 indicate low association, between
0.40 and 0.75 indicate medium association, and values greater
than 0.75 indicate high association between two measures.
Screening capabilities of HRM and the consistency of the analysis
were measure using classical metrics, such as sensitivity, specificity,
false negative and positive rates, considering sequencing analysis as
the standard measurement for both frozen and paraffin-embedded
extracted samples.
Statistical analyses were conducted using MicrosoftH Excel
(Redmond, WA) and R statistical package (www.r-project.org/).
Results
Frozen samples
Mutation screening was performed on 12 amplicons for each of
216 frozen samples during the initial HRM analysis (2,592
different determinations). We observed 59 HRM positive samples,
2510 HRM negative, and only 23 of these measurements were not
evaluable (less than 1%). For the repeat HRM experiments, 47
were positive, 156 negative, and only 1 out of 204 was not
evaluable. In total, 2,772 out of 2,796 (2,592 in first HRM round,
and 204 in the second HRM round), or 99.1%, experiments were
evaluable for screening of mutations/variants by HRM analysis.
In the initial round of analysis, 4 assays had no mutation
detected: ERBB2 exon 25, the distal region of TP53 exon 5,
GATA3 exon 5, and the proximal region of GATA3 exon 6. For the
remainder tested exons, between 1 to 9 putative nucleotide
substitutions were detected; notably exon 13 of FGFR3 had the
highest number, 30. The results of mutation screening by HRM
technology in both experiments, initial and repeat, as well as the
validation with sequencing for frozen samples are displayed in
Table 2.
HRM experiments were repeated on all the samples with
evidence of a putative mutation on the HRM curve, and also in a
subset of negative samples. The agreement between the initial and
repeat screen of HRM experiments was 91%, with a kappa test
value of 0.77, or high concordance between both. In general,
HRM curves presented similar shapes in both independent
analyses (Figure S2). The majority of disagreements resided in
samples called abnormal in the initial screen and normal, or
without mutation, in the repeat HRM experiment (n=12), that
were confirmed normal by sequencing. Only 1 repeated HRM
analysis failed to detect a nucleotide substitution in a sample with
respect to the initial screen. Later sequencing of this sample
detected a substitution of reference GG alleles, at position
7518234 of chromosome 17 (exon 7 of gene TP53), by AA.
The sensitivity and specificity for mutation/variant screening
were 97% and 87% respectively when compared to bi-directional
sequencing, with a false negative rate of 3%. The overall accuracy
of the test was 89% (Table 3). When the second, repeated HRM
analysis was compared to sequencing results, specificity increased
to 94%, as well as the accuracy, 94% (kappa of 0.82); but the false
negative rate also increased to 5%. Details of sequencing results for
mutations are described in Table 4. One false negative was
detected when comparing HRM experiments with sequencing,
failing to detect a nucleotide change, from AA to AG, in both the
initial and repeat screens. This variant turned out to be a known
SNP in exon 13 of FGFR3, rs7688609 (Table 4). Notably,
comprehensive public databases (dbSNP and Ensembl) indicated
G as the ancestral, reference allele in the DNA sequence for this
locus, but the majority of sequenced samples in our study, 63 out
of 67 (or 94%), were homozygous for AA, and only 6% were
heterozygous for G (GA). Given this disparity on allele frequencies
with available public data, we decided to sequence all 3
populations of HapMap as well as the SNP500 population for
this particular amplicon (n=366) [37,38]. Overall, allele A
frequency was 94%, and allele G frequency was 6%. Yoruba
population presented the highest G frequency with 17%. At the
same time, we sequenced this region for 43 available germ line
DNA from the patients suffering from these pediatric tumors; all of
them were homozygous for AA. After sequencing all paraffin-
embedded samples, we found similar allele frequencies.
Paraffin-embedded samples
The A260/A280 ratio, a measure of the purity of the paraffin-
embedded extracted DNA, had a mean of 1.92 (SD=0.45) for all
breast cancer samples, a mean of 1.82 (SD=0.12) for endometrial
cancer samples, and a mean of 2.0 (SD=0.27) for ovarian cancer
samples. There was a direct association between the concentration
of DNA (in ng/mL) extracted from the paraffin-embedded
samples, the DNA amount used for the pre-HRM PCR, and the
presence of a single band in the agarose gel (p,0.001). Also there
was an association between extracted DNA concentration and the
presence of an adequate HRM curve for analysis (p,0.001).
HRM was successful 96% of the time when the quantity of
paraffin-embedded extracted DNA used for this technique was
more than 30 ng in comparison with 92% when the quantity was
#30 ng (Table 5).
Overall, 93% (2,008 out of 2,153) of the measurements of
paraffin-embedded samples by HRM analysis were evaluable.
This technique was more successful when frozen DNA specimens
were analyzed than when DNA extracted from paraffin-embedded
samples was used, 99.1% versus 93.3% (p,0.001).
The results of the mutation screening by HRM technology and
its validation with bi-directional sequence analysis for the paraffin-
embedded samples are displayed in Table 6. Also, a representation
Detection of Somatic Mutations
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and specificity for the samples suspicious for mutation in the HRM
analysis were 88% and 80% respectively when compared to
sequencing, with a false negative rate of 12% (Table 7). However,
a relatively small percentage of DNA extracted from paraffin-
embedded samples was difficult to sequence. As we mentioned, the
sequence reaction was undertaken using amplified DNA from the
pre-HRM PCR. When sequencing of a particular assay failed,
genomic DNA was utilized and sequencing repeated. With this
strategy, confirmatory sequence in frozen samples could be
performed over 97% of the time. This was not the case with
DNA extracted from paraffin-embedded tissue, where sequencing
was achieved 80% of the time using the same strategy. In
particular, the success rate of DNA sequencing from paraffin-
embedded tissue was less than 50% for exons from genes TP53
(distal region of exon 5, and exon 7) and GATA3 (proximal region
of exon 6), affecting the comparison between sequence analysis
and HRM curves. Sequencing of these amplicons failed in 341 out
of 397 reactions, which accounted for 86% of all failed sequencing.
When these failed assays were excluded from the comparison
between HRM curves and sequencing, sensitivity increased to
92%, with an accuracy of 80%. Paraffin-embedded sequencing
details are described in Table S1. All new nucleotides changes
found on the study samples were submitted to dbSNP (build 131)
and displayed in Table S2.
Discussion
HRM analysis using the LightScanner
TM represents a moder-
ate-throughput screening test for mutations among candidate
genomic regions. The comparison with bi-directional sequencing
analysis provides strong evidence for its accuracy despite the low
prevalence mutation/variant rate, particularly since selected exons
harbored no mutations. Our results are consistent with earlier
reports [28,39]. The observed rate was 39 for 2,569 (or 1.5%)
mutation/variant for all analyzed exons within the 216 frozen
pediatric small rounded blue-cell tumors, and 67 for 1,586 (or
4.2%) mutation/variant for all analyzed exons in the 180
gynecological solid tumors (Tables 4 and S1, respectively).
Sensitivity and specificity of HRM analysis was higher in frozen
samples compared to paraffin-embedded samples, with an
observed sensitivity of 97% for DNA extracted from frozen
samples whereas it is 88% for DNA extracted from paraffin-
embedded tissue. Lower performance of some assays when
comparing DNA from paraffin-embedded specimens versus frozen
samples has also been described in previous studies for KRAS and
EGFR [12]. These differences are due, at least to some extent, to
sequence alterations in DNA related to cross-linking between
proteins and DNA, and inversely correlated with the number of
cells within the samples [40,41,42]. Also, the presence of multiple
mutations and point deletions may alter the efficiency of the assay,
possibly the reason for low performance in TP53 assays [16,43].
The majority of HRM studies performed to date have concluded
that, with some limitations, this is a relatively simple, rapid and
inexpensive technique for detecting genomic variation in paraffin-
embedded tissue samples [43]; with consistent reports on some of
the genes screened on our study [11,16,40,44]. Its limitations are
related to a lower efficiency on regions with deletions (or
insertions), on detecting homozygous variations (when compared
to heterozigous), on specific assays, and the lack of agreement on
the optimal length of PCR product or melting domains per
amplicon [12,13,16].
In order to eliminate the subtle differences in the reagent
components between the final elution buffers from multiple
Table 2. Results of mutation screening by HRM (initial screen and repeat) and sequencing from frozen samples.
HRM
positive
HRM
negative
Sequencing
positive
Sequencing
negative
Repeated
HRM positive
Repeated
HRM negative
PIK3CA61 0 2 2 1 3 252 5
ERBB262 5 0 2 1 5 080 8
KRAS62 3 2 1 3 553 5
TP5365(1) 5 206 3 7 5 7
TP5365(2) 0 215 0 15 1 14
TP5367 9 207 5 15 7 13
EGFR62 3 6 2 1 0 686 8
BRAF615 3 213 1 13 2 12
GATA365 0 2 1 6 080 8
GATA366(1) 0 216 0 10 0 10
GATA366(2) 1 215 1 16 1 16
FGFR3613 30 171 16 54 20 50
Total 59 2,510 39 164 47 156
doi:10.1371/journal.pone.0014522.t002
Table 3. Comparison between HRM mutation screening
(initial screen) and sequencing of frozen samples.
+ Sequencing 2 Sequencing Total
+ HRM 38 21 59
2 HRM 1 143 144
Total 39 164 203
Sensibility: 0.97.
Specificity: 0.87.
False positive: 0.13.
False negative: 0.03.
Accuracy: 0.89.
Note: These calculations are based uniquely on samples successfully
sequenced.
doi:10.1371/journal.pone.0014522.t003
Detection of Somatic Mutations
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e14522extraction platforms and to minimize variability within samples
our approach was to perform the DNA extraction using a
common extraction platform, conditions and protocol. With
optimized sample handling and standardized DNA extraction, it
is possible to screen paraffin-embedded samples with higher
sensitivity [40,41]. Despite the increased fragmentation of DNA
extracted from paraffin-embedded tissue, it is possible to reliably
screen shorter amplification products up to 250 bp in length. In
addition, the extent of DNA fragmentation correlates with tissue
type [12,45,46]. Success on both, HRM curve and sequencing
analyses, is over 97% when 10 ng of DNA is used from frozen
samples. But those results could not be achieved with the same
quantity of paraffin-embedded extracted DNA (successful HRM
analysis in 84%). By increasing the quantity of purified DNA
added to the pre-HRM PCR #30 ng performance improved,
partially overcoming the challenge posed by sub-optimal double
stranded DNA. Optimization of pre-HRM PCR can also mitigate
reduced sensitivity, especially while using special dye chemistry
[46].
DNA extracted from paraffin-embedded tissues was also more
difficult to sequence than DNA from frozen tissue [47,48].
Table 4. Mutation details from the sequencing analysis of frozen samples.
Gene Exon Chromosome Location Nucleotide Known SNP
Samples
affected
PIK3CA 10 3 180418785 G/A No 1
10 3 180418867 A/T No 1
FGFR3** 13 4 1777618 G/A No 1
13 4 1777626 C/T No 1
13 4 1777647 C/G No 1
13 4 1777674 C/T No 1
13 4 1777692 A/G** rs7688609 4
13 4 1777713 G/C rs17886888 1
13 4 1777720 G/A rs3135898 9
ERBB2 25 17 - - -
TP53 5(1) 17 7519251 G/T No 2
5(1) 17 7519188 G/A No 1
5(1) 17 7519200 Del(cgcccggcaccc) No 1
5(1) 17 7519198 Del(cccggcaccc) No 1
5(2) 17 - - -
TP53* 7 17 7518317 C/T* No 1
7 17 7518315 A/C* No 1
7 17 7518269 T/G TP53-147 (Poly-0023190) 1
7 17 7518264 C/T TP53-148 (Poly-0023191) 1
7 17 7518263 G/A rs11540652 1
7 17 7518234 G/A No 1
EGFR 23 7 55226944 C/T rs17290559 6
KRAS 2 12 25289548 G/A No 2
2 12 25289551 G/A No 1
BRAF 15 7 140099605 T/A BRAF-01(Poly-0019246) 1
GATA3 51 0 - - -
GATA3 6(1) 10 - - -
6(2) 10 8155836 C/T GATA3-54 (Poly-0008004) 1
*One sample had 2 mutation/variants.
**Both, dbSNP and Ensembl, appoint G as the ancestral allele; but the overall allele frequency in both reports was 96% for A and 4% for G.
doi:10.1371/journal.pone.0014522.t004
Table 5. Correlation between the quantity of DNA extracted
from the paraffin-embedded tissue, used for pre-HRM PCR,
and a band in the gel (p,0.001). Also, correlation between
DNA quantity and the presence of a HRM curve (p,0.001).
Band in gel
DNA (ng/mL) Yes No Total %
0–30 444 72 516 0.86
.30 196 8 204 0.96
Total 640 80 720 0.89
HRM curve
DNA (ng/mL) Yes No Total %
0–30 1,272 114 1,386 0.92
.30 736 31 767 0.96
Total 2,008 145 2,153 0.93
doi:10.1371/journal.pone.0014522.t005
Detection of Somatic Mutations
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optimized protocol for sequencing of DNA extracted from
paraffin-embedded tissue, but to assess the screening capabilities
of the HRM analysis. Once optimal experimental conditions for
HRM and sequencing analyses on the frozen samples were
determined, we applied them to the paraffin-embedded set, to
attain a fair comparison between both sets of samples. Protocol
modifications of sequencing experiments could modestly improve
performance, such as the use of whole genome amplification
[49,50], but this can introduce loss of heterozygosity. Steps to
optimize sequencing can also include alternative primers or
denaturation conditions.
Based on these considerations, our recommendations to
maintain and, perhaps, enhance the screening capabilities of
HRM analysis for paraffin-embedded extracted samples with a
LightScanner
TM would include the following:
N Inclusion of $30 ng total genomic DNA may increase HRM
analysis success rate up to 96%.
N Pre-HRM PCR optimization should include careful primer
selection to reduce GC content, adequate amplicon size, and
optimal annealing temperature.
N Amplicons that failed sequencing over 50% of the times also
performed poorly during HRM analysis. So it may be
worthwhile to test the selected amplicons by sequencing a
few samples at the beginning of the experiment.
The false positive rate of HRM analysis in paraffin embedded
samples was approximately 20%, which implies that additional
sequencing is needed to improve accuracy in the subset of samples
with a putative mutation [12]. HRM analysis on frozen samples
only considered 59 of them abnormal, for 39 with real mutation/
variants. Thus, it would be necessary to sequence fewer samples
for each mutation. Therefore, not only the performance is better
in frozen samples with respect to paraffin-embedded samples, but
also cost-efficiency.
In conclusion, HRM analysis with the LightScanner
TM is a
promising screening tool for mutation/variant in somatic
DNA extracted from either frozen or paraffin-embedded sam-
ples, although overall accuracy is better in frozen specimens,
probably related to DNA quality. This method is able to detect
m u t a t i o n sa sw e l la sk n o w nS N P s ,e v e ni ng e n o m i cr e g i o n sw i t h
a low mutation prevalence rate in the range of 5% or perhaps
lower.
Supporting Information
Figure S1 Representation of HRM curve of BRAF exon 15 from
genomic DNA extracted from frozen samples. Red arrow: HRM
curves with a plot interpreted by the software to be suspicious of
harboring a nucleotide change or a mutation/variant. HRM was
repeated for all these samples, and all of them were sequenced.
Green arrows: HRM curves with minimal variations with respect
to the averaged wild-type curve. All these samples also were
sequenced and HRM was repeated. Black arrow: All normalized
HRM curves considered to have a wild-type sequence. 20%
of these samples were randomly chosen to be repeated and
sequenced as negative controls.
Found at: doi:10.1371/journal.pone.0014522.s001 (2.49 MB TIF)
Figure S2 Example of HRM output from genomic DNA from
tumor frozen samples set. A. Output of one of the 3 plates used for
the initial analysis of exon 2 of KRAS. Each square represents a
well: brown squares are negative controls; grey squares represent
samples with no mutation/variant; red squares represent possible
mutation/variant; and green are unknown for mutation/variant.
B. Normalized HRM curve from the same samples in the exon 2
of KRAS initial analysis. C. Normalized HRM curve of the
repeated KRAS analysis.
Found at: doi:10.1371/journal.pone.0014522.s002 (0.68 MB TIF)
Figure S3 Samples of mutation screening with HRM technology
and its validation with sequencing from paraffin-embedded
samples. A. One of the assays (EGFR) performed in paraffin-
embedded samples from breast cancer: 1. Normalized HRM
curves of the assay; 2. Segment of sample assembled trace after
sequencing, with the presence of a variant, where AA has replaced
both alleles GG. B. Endometrial paraffin-embedded samples for
KRAS. 1. Normalized HRM curves of the assay with elevated
number of positives samples observed in the HRM curves from
paraffin specimens compare to frozen samples; 2. Genotype GG
has been substituted by GA.
Found at: doi:10.1371/journal.pone.0014522.s003 (9.83 MB TIF)
Table S1 Mutation details from the sequencing analysis of
paraffin-embedded samples.
Found at: doi:10.1371/journal.pone.0014522.s004 (0.09 MB
DOC)
Table 6. Results of mutation screening by HRM and
sequencing from the paraffin-embedded samples.
HRM + HRM 2 Total Sequencing + Sequencing 2
PIK3CA610 26 73 99 69 3
ERBB2625 44 130 174 7 167
KRAS627 5 9 8 173 24 149
TP5365–1 13 158 171 7 164
TP5365–2 20 76 96 59 1
TP53673 2 7 30 22 8
EGFR623 26 146 172 7 165
BRAF615 26 142 168 1 167
GATA653 4 1 2 7 161 3 158
GATA66–1 8 50 58 05 8
GATA66–2 36 124 160 0 160
FGFR3613 53 71 124 5 119
Total 364 1,222 1,586 67 1,519
doi:10.1371/journal.pone.0014522.t006
Table 7. Comparison between HRM mutation screening and
sequencing of paraffin-embedded samples.
+ Sequencing 2 Sequencing Total
+ HRM 59 305 364
2 HRM 8 1,214 1,222
Total 67 1,519 1,586
Sensibility: 0.88.
Specificity: 0.80.
False positive: 0.20.
False negative: 0.12.
Accuracy: 0.80.
Note: These calculations are based uniquely on samples successfully
sequenced.
doi:10.1371/journal.pone.0014522.t007
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submitted to dbSNP (build 131).
Found at: doi:10.1371/journal.pone.0014522.s005 (0.09 MB
DOC)
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